Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 23;12(9):e056528.
doi: 10.1136/bmjopen-2021-056528.

Protocol for establishing a core outcome set for evaluation in studies of pulmonary exacerbations in people with cystic fibrosis

Charlie McLeod  1   2 , Alan Robert Smyth  3 , Mitch Messer  4 , Andre Schultz  5   6 , Jamie Wood  7 , Richard Norman  8 , Christopher C Blyth  4   2 , Steve Webb  9   10 , Zoe Elliott  11 , Donald Van Devanter  12 , Anne L Stephenson  13 , Allison Tong  14 , Thomas L Snelling  15
Affiliations

Protocol for establishing a core outcome set for evaluation in studies of pulmonary exacerbations in people with cystic fibrosis

Charlie McLeod et al. BMJ Open. .

Abstract

Introduction: Pulmonary exacerbations are associated with increased morbidity and mortality in people with cystic fibrosis (CF). There is no consensus about which outcomes should be evaluated in studies of pulmonary exacerbations or how these outcomes should be measured. Outcomes of importance to people with lived experience of the disease are frequently omitted or inconsistently reported in studies, which limits the value of such studies for informing practice and policy. To better standardise outcome reporting and measurement, we aim to develop a core outcome set for studies of pulmonary exacerbations in people with CF (COS-PEX) and consensus recommendations for measurement of core outcomes.

Methods and analysis: Preliminary work for development of COS-PEX has been reported, including (1) systematic reviews of outcomes and methods for measurement reported in existing studies of pulmonary exacerbations; (2) workshops with people affected by CF within Australia; and (3) a Bayesian knowledge expert elicitation workshop with health professionals to ascertain outcomes of importance. Here we describe a protocol for the additional stages required for COS-PEX development and consensus methods for measurement of core outcomes. These include (1) an international two-round online Delphi survey and (2) consensus workshops to review and endorse the proposed COS-PEX and to agree with methods for measurement.

Ethics and dissemination: National mutual ethics scheme approval has been provided by the Child and Adolescent Health Service Human Research Ethics Committee (RGS 4926). Results will be disseminated via consumer and research networks and peer-reviewed publications. This study is registered with the Core Outcome Measures in Effectiveness Trials database.

Keywords: Cystic fibrosis; QUALITATIVE RESEARCH; RESPIRATORY MEDICINE (see Thoracic Medicine).

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Method for development of core outcome set for studies of pulmonary exacerbations in people with CF (COS-PEX).
Figure 2
Figure 2
Core outcome set for studies of pulmonary exacerbations in people with CF (COS-PEX).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hurley MN, Prayle AP, Flume P. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst Rev 2015;7:CD009730. 10.1002/14651858.CD009730.pub2 - DOI - PMC - PubMed
    1. Abbott L, Plummer A, Hoo ZH, et al. . Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2019;9:CD006682. 10.1002/14651858.CD006682.pub6 - DOI - PMC - PubMed
    1. Bhatt J, Jahnke N, Smyth AR. Once-Daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2019;9:CD002009. 10.1002/14651858.CD002009.pub7 - DOI - PMC - PubMed
    1. Smith S, Rowbotham NJ, Charbek E. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2018;10:CD008319. 10.1002/14651858.CD008319.pub3 - DOI - PMC - PubMed
    1. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2015;11:CD006961. 10.1002/14651858.CD006961.pub3 - DOI - PubMed

Publication types